Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | PLK1 | P53350 | 3/20 | 0.60 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 5/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13520263 | 0.88 | PLK1 (0.72) | GAAPLK1BRD4CNR1ALDH1A1 | |
| SCHEMBL13485805 | 0.83 | HDAC8 (0.56) | GAAPLK1CXCR5SCN9ACNR1 | |
| SCHEMBL8330859 | 0.81 | BRD4 (0.54) | PLK1CXCR5BRD4SCN9ACNR1 | |
| SCHEMBL24080315 | 0.79 | PLK1 (0.62) | GAAPLK1BRD4CNR1YTHDC1 | |
| SCHEMBL10942371 | 0.79 | PLK1 (0.62) | GAAPLK1BRD4CNR1YTHDC1 | |
| SCHEMBL15587625 | 0.79 | PLK1 (0.62) | GAAPLK1BRD4CNR1CNR2 | |
| SCHEMBL29392762 | 0.79 | CNR1 (0.47) | GAACXCR5BRD4CNR1CNR2 | |
| SCHEMBL401068 | 0.79 | CNR1 (0.47) | GAACXCR5BRD4CNR1CNR2 | |
| SCHEMBL11553077 | 0.78 | PLK1 (0.60) | GAAPLK1BRD4CNR1ALDH1A1 | |
| SCHEMBL1096857 | 0.78 | BRD4 (0.50) | GAACXCR5BRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | GAA 1904/4885PLK1 4475/4885CXCR5 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.